An analysis of participants from 16 clinical trials who were accidentally exposed to ixekizumab during pregnancy showed no signs of congenital malformations outcomes .
In an analysis, presented by Prof. Alexander Egeberg (Herlev and Gentofte Hospital, Denmark), pregnancy outcomes of patients exposed to the interleukin(IL)-17 blocker ixekizumab in clinical trials were assessed and compared with respective US National Vital Statistic System (NVSS; 2017) birth records and data from the multicentre longitudinal, observational registry PSOLAR (Psoriasis Longitudinal Assessment and Registry; June 2007 to August 2012). In total, 2,499 female and 4,517 male patients fathering a pregnancy were exposed to ixekizumab in 16 clinical trials. Data on live births, spontaneous and induced abortions, and congenital malformations were provided for maternal and paternal exposures.
Most female patients were exposed to ixekizumab during the first trimester (n=46; 92%). Out of 50 female patients (2%) who were exposed during the pregnancy, 44 had a known outcome. These pregnancies lead to 24 live births (54.5%); 75% of them were full term, 16.7% premature. There were 9 spontaneous abortions (20.5%) and 11 induced abortions (25%). No congenital malformations were reported for women exposed to ixekizumab during the pregnancy.
The analysis also included 76 men (1.7%) who were exposed to ixekizumab and who fathered a child. Of these pregnancies, 64 had a known outcome. They resulted in 51 live births (79.7%); 44 of them (86.3%) were full term, and 5 (9.8%) premature. There were 10 spontaneous (15.6%) and 3 induced abortions (4.7%). Five (7.8%) congenital malformations were reported for paternal exposure (i.e. heart abnormality, triplets, low birth weight, abnormal growth according to ultrasound, webbed fingers, and widening of right pelvis). In the PSOLAR registry, 93% of live births were full term, and 90% in US birth records . Reporting rates of spontaneous and induced abortions in PSOLAR were 21.7% and 7.2%, respectively.
Although data on pregnancies in patients with psoriasis or psoriatic arthritis exposed to ixekizumab in clinical studies are limited due to the small number of events and the short exposure/observation periods, they complement the available information. Reported pregnancy outcomes in patients exposed to ixekizumab were comparable with reports from female patients in PSOLAR and in the US birth records. “Despite the limitations, this data is quite comforting to look at,” concluded Prof. Egeberg.
- Egeberg, A et al. Abstract No FC03.09, EADV 2019, 9-13 Oct, Madrid, Spain.
- Nash P, et al. Lancet 2017;389:2317-27.
« Letter from the Editor Next Article
The underestimated effect of visible light »
Table of Contents: EADV 2019
Letter from the Editor
IL-17A blocker effective in paediatric psoriasis patients
Rituximab beats mycophenolate mofetil in pemphigus vulgaris
Novel JAK1/2 inhibitor shows remarkable efficacy in alopecia areata
Acne highly influenced by climate, pollutants, and unhealthy diet
JAK inhibition plus TCS lead to high clearance rates in AD
No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD
Green light for a second JAK inhibitor in AD
Topical ruxolitinib effective in vitiligo
Small molecules: interesting novel treatment options in AD
IL-1⍺ blockade: a new treatment option in AD
IL-4/IL-13 blockade leads to rapid itch reduction in adolescents
How to manage conjunctivitis in AD patients treated with a biologic
Biologics: increasingly used in paediatric dermatology
Spotlight on Psoriasis
IL-17 blocker: effective and safe in patients with comorbidities
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker
Relationship psoriasis and NAFLD: new data on the hepato-dermal axis
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome
Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints
No hint of teratogenicity through ixekizumab
New Insights in Photoprotection
Systemic photoprotection: a valuable addition to topical sun protection
The underestimated effect of visible light
Comorbidities more common in chronic urticaria, psoriasis, and AD
D-Dimer as future biomarker in CSU management?
Ligelizumab for CSU: symptom control and high response rates in re-treatment
Rosacea – From New Spectrum to New Therapy
New guidance on rosacea therapy according to phenotype
Best of the Posters
Above-the-neck melanoma more prone to metastases
Reduced sleep quality in dermatoses influenced by itch and pain
Anxiety and depression are common in families of AD infants
Certolizumab pegol efficacious for head and neck psoriasis
Biologic psoriasis treatment to lower cardiovascular risk?
Selective IL-23 blocker safe in elderly psoriasis patients